Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Novasep Expands Commercial ADC Manufacturing Plant | Contract Pharma

What are you searching for?

Sign in
Breaking News

Novasep Expands Commercial ADC Manufacturing Plant

New HPAPI capacity at Le Mans facility boosts capabilities for anti-cancer therapies 


Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Novasep has invested $5.5 million to expand its highly potent active pharmaceutical ingredients (HPAPI) manufacturing capabilities at its Le Mans facility in France. The expansion has been fully qualified and is now being used to scale up validation of a commercial ADC (antibody drug conjugate) payload. 
 

 
HPAPI products must be produced under very strict regulatory conditions to prevent API substance from cross contamination and protect operators from the highly active properties of these products. CMOs increasingly need to upgrade their facilities with higher containment capabilities to meet these needs.
 


The Le Mans production facility combines chemical and purification capabilities to manufacture potent and extremely potent ADC payloads at commercial scale with an OEL (occupational exposure limit) lower than 30 ng/m3 at multi-kg scale per batch.
The production suite can also perform cryogenic chemistry at -60°C in hastelloy reactors. 

“We are pleased to see the Le Mans facility commissioned, fully operational and successfully FDA audited,” said Thierry Van Nieuwenhove president of the Synthesis Business unit at Novasep. “There is a high demand from the pharmaceutical industry for CMOs to manufacture potent molecules for use in drugs that improve efficacy and reduce side effects. Novasep has the development and manufacturing capacity, level of specialization and experience to safely address the needs of this market.” 
 

 
 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics